Advertisement covers IDWeek 2013
Top Stories
thumbnail image for blurb

Suicide Risk Doubles Among HIV-Infected People Taking Efavirenz, Study Finds

Suicides among people with HIV on antiretroviral therapy are uncommon, but they appear to occur with significantly greater frequency among those who take efavirenz (Sustiva, Stocrin), according to an analysis presented at IDWeek 2013.

thumbnail image for blurb

Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds

Newly presented, 48-week findings provide further support for the favorable lipid profile of rilpivirine/tenofovir/emtricitabine relative to some of the more commonly prescribed boosted-PI regimens.

thumbnail image for blurb

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

Once-a-month HIV antiretroviral dosing is no longer a fanciful dream, so it's not outlandish for us to start thinking about where these drugs might fit into the HIV treatment armamentarium once they arrive.

More IDWeek 2013 Headlines:

About This Conference is an independent website not associated with this conference.

IDWeek 2013 is the second annual combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). It features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases -- including HIV -- across a patient's lifespan.

For more information on IDWeek 2013, please visit the conference's website. You may also view the interactive program planner.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.